FDA DRUG AD DIVISION ACTING DIRECTOR ROSE IS FORMER MEAD JOHNSON SALES EXEC
FDA DRUG AD DIVISION ACTING DIRECTOR ROSE IS FORMER MEAD JOHNSON SALES EXEC with seven years of experience in pharmaceutical sales. Janet "Lucy" Rose has been a reviewer in the ad division since joining FDA in November 1992. She is assuming the acting director position on a 120-day appointment. Office of Drug Standards Acting Director James Morrison had been heading the division as interim director. The agency said it has begun a search for a permanent director and deputy director. It is believed that FDA management wants a physician to fill the director slot on a permanent basis. Rose joined FDA from Bristol-Myers Squibb's Mead Johnson Pharmaceuticals division, where she was a district sales manager based in Washington, D.C. Rose had been with Mead Johnson since 1985 and moved up the sales ranks to her most recent position. Before joining the firm, she served three years as an instructor in the medical assistant program at Rochester Community College in Minnesota and prior to that was a physician's assistant at Salem College in Winston- Salem, N.C. Previous ad division Acting Director Cheryl Graham, MD, left FDA in late February to join Biometric Research Institute, headquartered in Washington, D.C., as senior technical advisor. Graham was promoted to the post from deputy director in April 1992 when division Director Ann Witt left DDMAC to join an internal agency advisory group for the Center for Devices & Radiological Health ("The Pink Sheet" April 13, 1992, T&G-6).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth